Public tracker of US drug prices vs international prices and deal terms

Public tracker of US drug prices vs international prices and deal terms targets a $3.0B = 10,000 payers & hospitals × $200K ACV + 50,000 clinics & employers × $20K ACV total addressable market with medium saturation and a year-over-year growth rate of 10% YoY (based on growth in health data/analytics spending and public-interest pricing tools; sources include IQVIA, Statista healthcare analytics growth estimates).

Key trends driving demand: Trend — Government and public scrutiny of drug pricing is increasing, which creates demand for transparent data that can be used in policy debates.; Trend — International reference pricing and cross-border procurement agreements are being reported more frequently, increasing the need for tools that compare prices and contractual terms.; Trend — Advances in NLP and LLMs make automated extraction of contractual concessions and regulatory filings feasible at scale, lowering the cost of producing structured deal datasets.; Trend — Pay-for-data procurement and API-first models are becoming standard in healthcare analytics, enabling subscription and API monetization strategies..